Merck consolidates global respiratory into Interpublic's Area 23

Share this article:
Merck consolidated the advertising and promotion business on its respiratory franchise to Interpublic, with Draftfcb Healthcare's Area 23 serving as lead agency. 

The assignment, which includes blockbuster brands like Singulair, Nasonex and newly-launched Dulera, spans healthcare professional and consumer advertising, medical education and managed care for asthma, allergy and COPD brands. It was previously split between several agencies: Juice handled Singulair, having relieved Draftfcb of the business back in 1998; DDB handled Nasonex; and CDM Princeton handled Dulera (Zenhale, ex-US), which launched for asthma last year and is now pursuing a COPD indication. In addition, the account includes Merck's investigational oral allergy immunotherapy tablet, now in phase 3 clinical trials, which was previously handled by LLNS. 

Draftfcb handles the advertising business on Merck's cardiovascular and metabolic franchise, including Januvia. 

“Merck has been a long-standing client of the Draftfcb Healthcare network,” said Dana Maiman, CEO of Draftfcb Healthcare. “As a matter of fact, it was our first client more than 30 years ago and we are honored to deepen our incredibly successful partnership with them.”

In fact, both Area 23 co-managing directors -- EVP Renee Mellas and creative director Tim Hawkey -- are old Draftfcb hands who came up in the business working on Merck brands like Zocor and Fosamax. The full-service spinoff shop launched in 2007.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...